Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

Arthritis Life

Becoming an Advocate with Lupus and Type 1 Diabetes: Melissa’s Story

17 May 2022

Description

Melissa shares how she learned to be a more effective advocate over time, and provides insights into how she copes with the ups and downs of chronic illness life.Episode at a glance:Melissa’s Diagnosis story for Lupus & Type 1 Diabetes as a nine year oldMelissa becomes a mental health occupational therapist while managing her conditionsMelissa shares her treatment ups and downs for lupus, including medications and lifestyle factors such as exercise and stress managementAdvocacy: Melissa shares her journey towards becoming a health advocateWhat to do when your supporters or caregivers don’t “get it?”Melissa’s Best Advice for people newly diagnosed with Lupus and/or Type 1 DiabetesMelissa’s Mental health / coping tips for chronic illness lifeMedical disclaimer:All content found on Arthritis Life public channels was created for generalized informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.Episode SponsorsRheum to THRIVE, a community support & education program Cheryl created to help people with rheumatic disease go from overwhelmed, confused and alone to confident, supported and connected. Join the waitlist for the next group, which starts in September 2022!Rheumatoid Arthritis Roadmap, a self-paced online course Cheryl created that teaches you how to confidently manage your physical, social and emotional life with rheumatoid arthritis. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.